FCGR2A and neoplasm: Additionally, Fc-silent mutations (e.g., L234F, L235E, N297G) can prevent nonspecific immune activation via CD3/FcγR crosslinking, enhancing T cell recruitment to the tumor microenvironment (TME) and limiting complement activation.